Dentsply Sirona Beats Q2 EPS Estimates at $0.52 and Reaffirms FY2026 Targets
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Healthcare consumable segment revenue growth of 7.1% offsets cyclical dental equipment declines, sustaining full-year operating earnings targets of $1.40 to $1.50 per share for XRAY.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factDENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, beating consensus estimates of $0.36. |
| What else was confirmed? | Reported factRevenues declined 4.1% year-over-year during the quarter. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for XRAY yet — this is the next research task. |
| What would change the assessment? | UnknownDental Consumables vs Equipment Order Mix — Track product line revenue split details in SEC Form 10-Q filing. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, beating consensus estimates of $0.36.
- · Revenues declined 4.1% year-over-year during the quarter.
- · Wellspect Healthcare segment revenue grew 7.1%.
- · The company reaffirmed full-year 2026 sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.
Public research record
Research framework · page evidenceCompleted event assessment
healthcare consumable sales resilience offsetting equipment revenue declines
| Type | Claim | Scope |
|---|---|---|
| Assumption | DENTSPLY SIRONA reported Q2 adjusted EPS of $0.52, beating consensus estimates of $0.36. | 2026-09-09 |
| Interpretation | healthcare consumable sales resilience offsetting equipment revenue declines | XRAY |
Countercase, invalidators, and sources
Equipment order demand stabilizes alongside Wellspect growth, pushing EPS toward the upper end of $1.50 guidance.
- · Dental Consumables vs Equipment Order Mix — Track product line revenue split details in SEC Form 10-Q filing.
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure · 2026-09-08
What remains unresolved
- Base path
- Reaffirmed full-year 2026 revenue of $3.5B-$3.6B and EPS of $1.40-$1.50 met via cost containment.
- Adverse path
- Further contraction in elective dental procedures drags full-year sales below $3.5 billion.
- Supportive path
- Equipment order demand stabilizes alongside Wellspect growth, pushing EPS toward the upper end of $1.50 guidance.
- · Dental Consumables vs Equipment Order Mix — Track product line revenue split details in SEC Form 10-Q filing.this week
Evidence
- XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure2026-09-08
“DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS.”
Supports: XRAY beat Q2 EPS with $0.52 vs $0.36 consensus and reaffirmed FY2026 guidance.